Baker Bros. Advisors LP Dyne Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $7.9 Billion
- Q1 2024
A detailed history of Baker Bros. Advisors LP transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 285,000 shares of DYN stock, worth $10.1 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
285,000Holding current value
$10.1 Million% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
176Shares Held
87.1MCall Options Held
130KPut Options Held
209K-
Atlas Venture Life Science Advisors, LLC8.02MShares$283 Million28.49% of portfolio
-
Fcpm Iii Services B.V. Naarden, P77.85MShares$277 Million31.49% of portfolio
-
Black Rock Inc. New York, NY5.39MShares$190 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT4.56MShares$161 Million4.27% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.25MShares$150 Million0.02% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $1.83B
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...